Glaukos Corporation (GKOS)
USD 145.14
(-0.83%)
USD 145.14
(-0.83%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -128.7 Million USD | -25.79% |
| 2022 | -102.31 Million USD | -62.73% |
| 2021 | -62.87 Million USD | 49.11% |
| 2020 | -123.55 Million USD | -145.67% |
| 2019 | -50.29 Million USD | -286.8% |
| 2018 | -13 Million USD | -470.01% |
| 2017 | -2.28 Million USD | -153.78% |
| 2016 | 4.24 Million USD | 141.19% |
| 2015 | -10.29 Million USD | 21.83% |
| 2014 | -13.17 Million USD | 7.23% |
| 2013 | -14.19 Million USD | 35.75% |
| 2012 | -22.09 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -27.33 Million USD | 29.22% |
| 2024 Q2 | -27.47 Million USD | -0.5% |
| 2024 Q3 | -24.66 Million USD | 10.24% |
| 2023 Q3 | -28.01 Million USD | 3.66% |
| 2023 Q2 | -29.07 Million USD | 11.88% |
| 2023 FY | -128.7 Million USD | -25.79% |
| 2023 Q4 | -38.62 Million USD | -37.89% |
| 2023 Q1 | -32.99 Million USD | 2.2% |
| 2022 Q3 | -21.61 Million USD | 41.21% |
| 2022 Q4 | -33.73 Million USD | -56.1% |
| 2022 FY | -102.31 Million USD | -62.73% |
| 2022 Q1 | -20.2 Million USD | -13.09% |
| 2022 Q2 | -36.76 Million USD | -81.91% |
| 2021 Q2 | -14.22 Million USD | -20.47% |
| 2021 Q4 | -17.86 Million USD | -262.09% |
| 2021 Q3 | 11.02 Million USD | 177.51% |
| 2021 FY | -62.87 Million USD | 49.11% |
| 2021 Q1 | -11.8 Million USD | -3.63% |
| 2020 Q1 | -52.61 Million USD | -77.16% |
| 2020 Q2 | -47.19 Million USD | 10.29% |
| 2020 Q3 | -12.35 Million USD | 73.83% |
| 2020 Q4 | -11.39 Million USD | 7.77% |
| 2020 FY | -123.55 Million USD | -145.67% |
| 2019 Q4 | -29.69 Million USD | -139.2% |
| 2019 FY | -50.29 Million USD | -286.8% |
| 2019 Q3 | -12.41 Million USD | -98.96% |
| 2019 Q2 | -6.24 Million USD | -221.65% |
| 2019 Q1 | -1.94 Million USD | -202.27% |
| 2018 Q4 | 1.89 Million USD | 127.35% |
| 2018 FY | -13 Million USD | -470.01% |
| 2018 Q2 | -4.24 Million USD | -14.38% |
| 2018 Q1 | -3.71 Million USD | -798.12% |
| 2018 Q3 | -6.93 Million USD | -63.3% |
| 2017 Q4 | 532 Thousand USD | -28.88% |
| 2017 FY | -2.28 Million USD | -153.78% |
| 2017 Q1 | 304 Thousand USD | -35.04% |
| 2017 Q2 | -3.86 Million USD | -1371.38% |
| 2017 Q3 | 748 Thousand USD | 119.35% |
| 2016 FY | 4.24 Million USD | 141.19% |
| 2016 Q2 | 2.12 Million USD | 241.71% |
| 2016 Q3 | 1.03 Million USD | -51.46% |
| 2016 Q1 | 621 Thousand USD | 130.97% |
| 2016 Q4 | 468 Thousand USD | -54.56% |
| 2015 FY | -10.29 Million USD | 21.83% |
| 2015 Q4 | -2 Million USD | -16.23% |
| 2015 Q3 | -1.72 Million USD | 67.95% |
| 2015 Q2 | -5.38 Million USD | -354.56% |
| 2015 Q1 | -1.18 Million USD | 76.41% |
| 2014 Q2 | -2.24 Million USD | 44.26% |
| 2014 Q3 | -1.88 Million USD | 16.13% |
| 2014 Q1 | -4.02 Million USD | -17.63% |
| 2014 Q4 | -5.01 Million USD | -166.68% |
| 2014 FY | -13.17 Million USD | 7.23% |
| 2013 Q3 | -3.42 Million USD | -5.02% |
| 2013 Q1 | -4.09 Million USD | 0.0% |
| 2013 Q2 | -3.25 Million USD | 20.4% |
| 2013 Q4 | -3.42 Million USD | 0.0% |
| 2013 FY | -14.19 Million USD | 35.75% |
| 2012 FY | -22.09 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Abbott Laboratories | 6.47 Billion USD | 101.987% |
| Allurion Technologies Inc. | -78.07 Million USD | -64.835% |
| Artivion, Inc. | 5.74 Million USD | 2341.379% |
| Avanos Medical, Inc. | 4.2 Million USD | 3164.286% |
| Butterfly Network, Inc. | -145.61 Million USD | 11.613% |
| Butterfly Network, Inc. | -145.61 Million USD | 11.613% |
| Bio-Rad Laboratories, Inc. | 383.79 Million USD | 133.533% |
| Boston Scientific Corporation | 2.34 Billion USD | 105.493% |
| Perspective Therapeutics, Inc. | -15.18 Million USD | -747.714% |
| CONMED Corporation | 130.78 Million USD | 198.405% |
| Edwards Lifesciences Corporation | 1.53 Billion USD | 108.389% |
| Paragon 28, Inc. | -37.3 Million USD | -244.957% |
| Globus Medical, Inc. | 133.14 Million USD | 196.664% |
| Inspire Medical Systems, Inc. | -40.27 Million USD | -219.585% |
| Integer Holdings Corporation | 167.33 Million USD | 176.914% |
| Medtronic plc | 5.14 Billion USD | 102.502% |
| Nevro Corp. | -99.3 Million USD | -29.597% |
| Owlet, Inc. | -28.63 Million USD | -349.497% |
| Penumbra, Inc. | 73.55 Million USD | 274.981% |
| Vicarious Surgical Inc. | -80.66 Million USD | -59.547% |
| Smith & Nephew plc | 425 Million USD | 130.282% |
| Sonendo, Inc. | -57.74 Million USD | -122.884% |
| STERIS plc | 836.11 Million USD | 115.393% |
| Stryker Corporation | 3.88 Billion USD | 103.31% |
| Vapotherm, Inc. | -39.08 Million USD | -229.324% |
| Zimmer Biomet Holdings, Inc. | 1.27 Billion USD | 110.073% |